News | April 25, 2007

Cardiologist Launches New Heart Supplements

April 26, 2007 — Cardiologist Lee A. Surkin, M.D., FAAC, is set to launch a new line of cardiac nutritional supplements this July. He says the new Cardiac Wellness Supplements are designed to complement, not replace, standard cardiovascular disease prevention and treatment therapies.

"Simply put, I developed Cardiac Wellness Supplements out of necessity," said Dr. Surkin. "I believe in an integrative approach to the prevention and treatment of cardiovascular disease. That means traditional medical care, exercise, and basic nutrition. As my patients became more educated, they asked me for recommendations for supplements to help improve their nutrition. I wasn't able to find the right supplements to meet their needs, so I developed my own proprietary line of products that I am now bringing to a broader market."

"Supplements are a worrisome area for many physicians because in most cases there is a real lack of solid scientific data to support safety or outcome," said Dr. Surkin. "As I looked at products available in the marketplace, I found few suitable options. And of the products I was comfortable recommending, expense was almost always an obstacle. Now, with my Wellcor Products, I can comfortably recommend products that have data to support them and are cost-effective."

Dr. Surkin utilized his training in human nutrition and cardiology to develop Cardiac Wellness Supplements, focusing on ingredients that have substantial scientific data on safety, efficacy and dosage. The product line will include five products: Wellcor Defense -- Omega 3, Wellcor Energize -- Supreme Green Tea, Wellcor Guard -- Resveratrol / Quercitin, Wellcor Strength -- CoEnzyme Q10 / Hawthorn and Wellcor Control -- Alpha-Lipoic Acid / L- Carnitine.
For more information visit www.cardiacwellness.com.


Related Content

News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
News | Pharmaceuticals

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Home November 21, 2023
Home
Feature | Pharmaceuticals | By Christine Book

In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor ...

Home October 25, 2023
Home
Videos | Pharmaceuticals

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

Home September 26, 2023
Home
Videos | Pharmaceuticals

In Part 2 of DAIC’s 3-part “One on One” series with Dr. Christine Seidman, a discussion on the discovery of gene-based ...

Home September 11, 2023
Home
Videos | Pharmaceuticals

A 3-part video series with Christine E. Seidman, MD, FACC, FAHA In the first of this 3-part “One on One” series, Dr ...

Home August 28, 2023
Home
News | Pharmaceuticals

August 1, 2023 —LEXEO Therapeutics, a clinical-stage gene therapy company advancing adeno-associated virus (AAV)-based ...

Home August 01, 2023
Home
News | Pharmaceuticals

July 10, 2023 — Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio ...

Home July 10, 2023
Home
Subscribe Now